Free Trial

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update

Verrica Pharmaceuticals logo with Medical background

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 2,270,000 shares, a drop of 27.9% from the May 15th total of 3,150,000 shares. Approximately 8.7% of the company's stock are short sold. Based on an average daily trading volume, of 381,600 shares, the days-to-cover ratio is presently 5.9 days.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of Verrica Pharmaceuticals by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 477,269 shares of the company's stock worth $334,000 after acquiring an additional 21,789 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Verrica Pharmaceuticals by 23.3% in the first quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock worth $61,000 after acquiring an additional 26,308 shares during the period. Invesco Ltd. raised its position in shares of Verrica Pharmaceuticals by 64.8% in the first quarter. Invesco Ltd. now owns 74,388 shares of the company's stock worth $33,000 after acquiring an additional 29,256 shares during the period. AQR Capital Management LLC raised its position in shares of Verrica Pharmaceuticals by 306.7% in the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after acquiring an additional 44,275 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Verrica Pharmaceuticals by 127.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company's stock worth $44,000 after acquiring an additional 55,852 shares during the period. Institutional investors and hedge funds own 42.45% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on VRCA shares. Wall Street Zen raised shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright reiterated a "neutral" rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, April 8th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Verrica Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $8.00.

Get Our Latest Report on Verrica Pharmaceuticals

Verrica Pharmaceuticals Trading Up 1.0%

Shares of Verrica Pharmaceuticals stock traded up $0.01 during trading hours on Friday, reaching $0.58. The stock had a trading volume of 368,610 shares, compared to its average volume of 590,322. The stock's 50 day moving average is $0.54 and its 200 day moving average is $0.62. The firm has a market capitalization of $54.09 million, a PE ratio of -0.49 and a beta of 1.75. Verrica Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $8.98.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04. The firm had revenue of $3.44 million during the quarter, compared to analyst estimates of $2.53 million. As a group, sell-side analysts predict that Verrica Pharmaceuticals will post -1.46 earnings per share for the current year.

Verrica Pharmaceuticals Company Profile

(Get Free Report)

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.

See Also

Should You Invest $1,000 in Verrica Pharmaceuticals Right Now?

Before you consider Verrica Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.

While Verrica Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines